KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of a novel sodium picosulfate oral tablet in a randomized controlled trial for bowel preparation.

Su Bum Park, Sang Bum Kang, Geom Seog Seo, Chang Soo Eun, Chang Hwan Choi, Dong-Hoon Yang, Jae Jun Park, Chang Mo Moon, Sung Hoon Jung, Hyung Park, Mi Hee Park, Ho Kyun Yoo, Jiwon Kim, Jung A Heo, Dong Il Park

World J Gastroenterol 32(6) 113880

PMID41695285
PMCIDPMC12898274
DOI10.3748/wjg.v32.i6.113880
发表日期2026-02-16
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:非 KM 图;Figure 3:非 KM 图。
摘要

摘要

BACKGROUND: Oral sulfate tablets (OSTs) are commonly used in South Korea, but the requirement to ingest 28 tablets and concerns regarding renal and gastrointestinal safety may reduce patient compliance. DWJ1609 is a novel OST formulation that contains sodium picosulfate and 25% less sulfate, requiring only 20 tablets. This modification is expected to improve tolerability while maintaining cleansing efficacy. AIM: To evaluate the bowel cleansing efficacy and safety of DWJ1609 compared with conventional OSTs and to assess adverse events. METHODS: This prospective, randomized, single-blinded (investigator), multicenter, phase III clinical trial was conducted at seven university hospitals in South Korea. The primary endpoint was the non-inferiority of DWJ1609 based on the proportion of participants achieving a "successful" grade A or B on the Harefield Cleansing Scale, as assessed by independent central readers. Safety was monitored through adverse events and laboratory evaluations. RESULTS: Overall, 215 participants were randomized, and 200 were included in the per-protocol analysis (DWJ1609: 99; OST: 101). Successful bowel cleansing was achieved in 96.97% of the DWJ1609 group, which was non-inferior to the OST group (100.00%), with a difference of 3.03%. DWJ1609 showed significantly higher tolerability, with lower incidence of nausea, headache, and dizziness, although vomiting occurred slightly more frequently. CONCLUSION: DWJ1609 demonstrated non-inferior bowel cleansing efficacy, improved tolerability, and a favorable safety profile compared with conventional. DWJ1609 has the potential to improve compliance and overall quality of colonoscopy.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Study flow diagram of participant selection. FAS: Full analysis set; OST: Oral sulfate tablet; PPS: Per-protocol set; SAF: Safety analysis set.
非 KM Figure
Figure 2Efficacy of bowel cleansing. OST: Oral sulfate tablet.
非 KM Figure
Figure 3Efficacy of bowel cleansing by segment. A: Assessed by independent central readers; B: Assessed by investigators. OST: Oral sulfate tablet.
非 KM Figure